GSK At J.P.M. Updates On Breo Launch, Rare Diseases
This article was originally published in The Pink Sheet Daily
Executive Summary
Following several setbacks in 2014, GSK’s rare disease business is “a work in progress” and the company will look for partnerships to maximize potential of its remaining assets in that category; meanwhile the closely watched Breo launch is meeting expectations despite bumps created when large pharmacy benefits managers, in highly publicized moves, took the drug off their formularies.